kynurenine has been researched along with Heart Failure in 10 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
Excerpt | Relevance | Reference |
---|---|---|
"Protocatechuic acid (3,4-dihydroxybenzoic acid) prevents oxidative stress, inflammation and cardiac hypertrophy." | 8.31 | Protocatechuic acid prevents isoproterenol-induced heart failure in mice by downregulating kynurenine-3-monooxygenase. ( Bai, L; Han, X; He, X; Jeon, MJ; Jeong, MH; Jeong, SM; Kee, HJ; Kee, SJ; Kim, SH; Zhou, H, 2023) |
"Metabolites of the kynurenine pathway (mKP) relate to important aspects of heart failure pathophysiology, such as inflammation, energy-homeostasis, apoptosis, and oxidative stress." | 7.96 | Plasma kynurenines and prognosis in patients with heart failure. ( Giil, LM; Lund, A; Midttun, Ø; Nordrehaug, JE; Nygård, O; Pedersen, EK; Slettom, G; Solvang, SH; Ueland, PM; Ulvik, A, 2020) |
"It was our objective to increase the body of data regarding the value of kynurenine as a biomarker in chronic heart failure (CHF)." | 7.91 | Plasma Kynurenine Predicts Severity and Complications of Heart Failure and Associates with Established Biochemical and Clinical Markers of Disease. ( Armbruster, FP; Bankovic, D; Boschann, F; Dschietzig, TB; Kellner, KH; Klüsener, R; Meinitzer, A; Melzer, C; Mitrovic, V; Ruppert, J; Sasse, K, 2019) |
"Kynurenine is a circulating metabolite from the essential amino acid tryptophan." | 6.82 | Impact of Plasma Kynurenine Level on Functional Capacity and Outcome in Heart Failure - Results From Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). ( Anker, SD; Doehner, W; Dschietzig, TB; Ebner, N; Konishi, M; Schefold, JC; Springer, J; von Haehling, S, 2016) |
"Protocatechuic acid (3,4-dihydroxybenzoic acid) prevents oxidative stress, inflammation and cardiac hypertrophy." | 4.31 | Protocatechuic acid prevents isoproterenol-induced heart failure in mice by downregulating kynurenine-3-monooxygenase. ( Bai, L; Han, X; He, X; Jeon, MJ; Jeong, MH; Jeong, SM; Kee, HJ; Kee, SJ; Kim, SH; Zhou, H, 2023) |
"Metabolites of the kynurenine pathway (mKP) relate to important aspects of heart failure pathophysiology, such as inflammation, energy-homeostasis, apoptosis, and oxidative stress." | 3.96 | Plasma kynurenines and prognosis in patients with heart failure. ( Giil, LM; Lund, A; Midttun, Ø; Nordrehaug, JE; Nygård, O; Pedersen, EK; Slettom, G; Solvang, SH; Ueland, PM; Ulvik, A, 2020) |
"It was our objective to increase the body of data regarding the value of kynurenine as a biomarker in chronic heart failure (CHF)." | 3.91 | Plasma Kynurenine Predicts Severity and Complications of Heart Failure and Associates with Established Biochemical and Clinical Markers of Disease. ( Armbruster, FP; Bankovic, D; Boschann, F; Dschietzig, TB; Kellner, KH; Klüsener, R; Meinitzer, A; Melzer, C; Mitrovic, V; Ruppert, J; Sasse, K, 2019) |
"Kynurenine is a circulating metabolite from the essential amino acid tryptophan." | 2.82 | Impact of Plasma Kynurenine Level on Functional Capacity and Outcome in Heart Failure - Results From Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). ( Anker, SD; Doehner, W; Dschietzig, TB; Ebner, N; Konishi, M; Schefold, JC; Springer, J; von Haehling, S, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (10.00) | 29.6817 |
2010's | 4 (40.00) | 24.3611 |
2020's | 5 (50.00) | 2.80 |
Authors | Studies |
---|---|
Bekfani, T | 1 |
Bekhite, M | 1 |
Neugebauer, S | 1 |
Derlien, S | 1 |
Hamadanchi, A | 1 |
Nisser, J | 1 |
Hilse, MS | 1 |
Haase, D | 1 |
Kretzschmar, T | 1 |
Wu, MF | 1 |
Lichtenauer, M | 1 |
Kiehntopf, M | 1 |
von Haehling, S | 2 |
Schlattmann, P | 1 |
Lehmann, G | 1 |
Franz, M | 1 |
Möbius-Winkler, S | 1 |
Schulze, C | 1 |
Bai, L | 1 |
Han, X | 1 |
Kee, HJ | 1 |
He, X | 1 |
Kim, SH | 1 |
Jeon, MJ | 1 |
Zhou, H | 1 |
Jeong, SM | 1 |
Kee, SJ | 1 |
Jeong, MH | 1 |
Lund, A | 1 |
Nordrehaug, JE | 1 |
Slettom, G | 1 |
Solvang, SH | 1 |
Pedersen, EK | 1 |
Midttun, Ø | 1 |
Ulvik, A | 1 |
Ueland, PM | 1 |
Nygård, O | 1 |
Giil, LM | 1 |
Sousa, A | 1 |
Ribeiro, C | 1 |
Gonçalves, VMF | 1 |
Barbosa, J | 1 |
Peixoto, B | 1 |
Andrade, A | 1 |
Silva, P | 1 |
Andrade, JP | 1 |
Leal, S | 1 |
Razquin, C | 1 |
Ruiz-Canela, M | 1 |
Toledo, E | 1 |
Hernández-Alonso, P | 1 |
Clish, CB | 1 |
Guasch-Ferré, M | 1 |
Li, J | 1 |
Wittenbecher, C | 1 |
Dennis, C | 1 |
Alonso-Gómez, A | 1 |
Fitó, M | 1 |
Liang, L | 1 |
Corella, D | 1 |
Gómez-Gracia, E | 1 |
Estruch, R | 1 |
Fiol, M | 1 |
Lapetra, J | 1 |
Serra-Majem, L | 1 |
Ros, E | 1 |
Aros, F | 1 |
Salas-Salvadó, J | 1 |
Hu, FB | 1 |
Martínez-González, MA | 1 |
Su, J | 1 |
Wang, J | 1 |
Ma, Y | 1 |
Li, Q | 1 |
Yang, Y | 1 |
Huang, L | 1 |
Wang, H | 1 |
Li, H | 1 |
Wang, Z | 1 |
Tong, J | 1 |
Huang, D | 1 |
Bai, X | 1 |
Yu, M | 1 |
Bu, L | 1 |
Fei, J | 1 |
Huang, F | 1 |
Dschietzig, TB | 2 |
Kellner, KH | 1 |
Sasse, K | 1 |
Boschann, F | 1 |
Klüsener, R | 1 |
Ruppert, J | 1 |
Armbruster, FP | 1 |
Bankovic, D | 1 |
Meinitzer, A | 1 |
Mitrovic, V | 1 |
Melzer, C | 1 |
Zhang, Y | 1 |
Blasco-Colmenares, E | 1 |
Harms, AC | 1 |
London, B | 1 |
Halder, I | 1 |
Singh, M | 1 |
Dudley, SC | 1 |
Gutmann, R | 1 |
Guallar, E | 1 |
Hankemeier, T | 1 |
Tomaselli, GF | 1 |
Cheng, A | 1 |
Konishi, M | 1 |
Ebner, N | 1 |
Springer, J | 1 |
Schefold, JC | 1 |
Doehner, W | 1 |
Anker, SD | 1 |
Schroecksnadel, K | 1 |
Wirleitner, B | 1 |
Fuchs, D | 1 |
2 trials available for kynurenine and Heart Failure
Article | Year |
---|---|
Metabolomics of the tryptophan-kynurenine degradation pathway and risk of atrial fibrillation and heart failure: potential modification effect of Mediterranean diet.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Case-Control Studies; Diet, Mediterranean; Female; Hea | 2021 |
Impact of Plasma Kynurenine Level on Functional Capacity and Outcome in Heart Failure - Results From Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).
Topics: Age Factors; Aged; Body Mass Index; Disease-Free Survival; Female; Heart Failure; Humans; Kidney; Ky | 2016 |
8 other studies available for kynurenine and Heart Failure
Article | Year |
---|---|
Metabolomic Profiling in Patients with Heart Failure and Exercise Intolerance: Kynurenine as a Potential Biomarker.
Topics: Biomarkers; Heart Failure; Humans; Kynurenine; Metabolomics; Stroke Volume | 2022 |
Protocatechuic acid prevents isoproterenol-induced heart failure in mice by downregulating kynurenine-3-monooxygenase.
Topics: Animals; Cardiomegaly; Heart Failure; Isoproterenol; Kynurenine; Kynurenine 3-Monooxygenase; Mice; M | 2023 |
Plasma kynurenines and prognosis in patients with heart failure.
Topics: Aged; Biomarkers; Case-Control Studies; Coronary Artery Disease; Female; Heart Failure; Humans; Kynu | 2020 |
Development and validation of a liquid chromatography method using UV/fluorescence detection for the quantitative determination of metabolites of the kynurenine pathway in human urine: Application to patients with heart failure.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Heart Failure; Humans; Kynurenine; Mal | 2021 |
Inflammation associated with chronic heart failure leads to enhanced susceptibility to depression.
Topics: Animals; Brain; Chronic Disease; Cytokines; Depression; Heart Failure; Hypothalamo-Hypophyseal Syste | 2019 |
Plasma Kynurenine Predicts Severity and Complications of Heart Failure and Associates with Established Biochemical and Clinical Markers of Disease.
Topics: Aged; Aged, 80 and over; Biomarkers; Chronic Disease; Female; Heart Failure; Humans; Immunoassay; Ky | 2019 |
Serum amine-based metabolites and their association with outcomes in primary prevention implantable cardioverter-defibrillator patients.
Topics: Aged; Amines; Arginine; Biomarkers; Death, Sudden, Cardiac; Defibrillators, Implantable; Electric Co | 2016 |
Anemia and congestive heart failure.
Topics: Anemia; Causality; Cell Division; Chronic Disease; Comorbidity; Dioxygenases; Heart Failure; Hematop | 2003 |